Patents Assigned to Ironwood Pharmaceuticals, Inc.
-
Patent number: 10702576Abstract: The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.Type: GrantFiled: January 17, 2019Date of Patent: July 7, 2020Assignees: IRONWOOD PHARMACEUTICALS, INC., FOREST LABORATORIES HOLDINGS LIMITEDInventors: Yun Mo, Angelika Fretzen, Brian Cali, Mahendra Dedhiya
-
Patent number: 10675325Abstract: The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.Type: GrantFiled: September 26, 2019Date of Patent: June 9, 2020Assignees: IRONWOOD PHARMACEUTICALS, INC., FOREST LABORATORIES HOLDINGS LIMITEDInventors: Yun Mo, Angelika Fretzen, Brian Cali, Mahendra Dedhiya
-
Publication number: 20200113931Abstract: Disclosed herein are oral dosage forms of colesevelam, or a pharmaceutically acceptable salt thereof, adapted to treat upper gastro-intestinal disorders associated with PPI refractory GERD. Also disclosed are the methods of using these oral dosage forms to treat upper gastrointestinal disorders associated with PPI refractory, or PPI resistant, GERD in a patient in need thereof. The oral dosage forms disclosed herein are adapted for the ascribed uses by being comprised of colesevelam, or a pharmaceutically acceptable salt thereof, in a polymeric matrix comprised of one or more hydrophilic polymers such that the oral dosage form erodes upon encountering gastric fluid and has a gastric retention time of three hours or longer, allowing for an extended period of time for the colesevelam to be released in the upper GI and sequester excess bile.Type: ApplicationFiled: May 28, 2019Publication date: April 16, 2020Applicant: Ironwood Pharmaceuticals, Inc.Inventors: Bernard Joseph Lavins, Mark G. Currie
-
Patent number: 10618938Abstract: The present invention provides peptides and compositions that are useful for the treatment of gastrointestinal disorders or for colon cleansing. The present invention also provides compositions and methods of treating gastrointestinal disorders and pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms.Type: GrantFiled: April 29, 2016Date of Patent: April 14, 2020Assignee: Ironwood Pharmaceuticals, Inc.Inventors: Mark G. Currie, Robert Solinga, Christopher Leitheiser
-
Patent number: 10266529Abstract: The present invention provides crystalline Forms FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and related methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using a crystalline Form FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and/or pharmaceutical compositions thereof.Type: GrantFiled: August 25, 2017Date of Patent: April 23, 2019Assignees: Bionomics Limited, Ironwood Pharmaceuticals, Inc.Inventors: Bernard Luke Flynn, Dharam Paul, Andrew John Harvey, Vasu V. Sethuraman, Raymond E. Forslund, Song Xue, Rob Livingston, Ahmad Hashash
-
Patent number: 10189809Abstract: Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.Type: GrantFiled: February 17, 2017Date of Patent: January 29, 2019Assignee: Ironwood Pharmaceuticals, Inc.Inventors: Charles Kim, Takashi Nakai, Thomas Wai-Ho Lee, Joel Moore, Nicholas Robert Perl, Jason Rohde, Rajesh R. Iyengar, Ara Mermerian, Angelika Fretzen
-
Patent number: 10183021Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.Type: GrantFiled: August 24, 2016Date of Patent: January 22, 2019Assignee: Ironwood Pharmaceuticals, Inc.Inventors: Takashi Nakai, James Jia, Paul Allan Renhowe, Timothy Claude Barden, Xiang Y. Yu, James Edward Sheppeck, Karthik Iyer, Joon Jung, George Todd Milne, Kimberly Kafadar Long, Mark G. Currie, Joel Moore, Nicholas Robert Perl, Rajesh R. Iyengar, Ara Mermerian, G-Yoon Jamie Im, Thomas Wai-Ho Lee, Colleen Hudson, Glen Robert Rennie
-
Publication number: 20180235878Abstract: Disclosed herein are novel compositions and methods for treating or preventing upper GI tract disorders and protecting stratified squamous epithelium against injury by a noxious substance. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant, alone or in combination with at least one proton pump inhibitor, and optionally one or more agent chosen from antacids, histamine H2-receptor antagonists, ?-aminobutyricacid-b (GABA-B) agonists, prodrugs of GABA-B agonists, and protease inhibitors.Type: ApplicationFiled: November 15, 2017Publication date: August 23, 2018Applicant: Ironwood Pharmaceuticals, Inc.Inventor: Mark CURRIE
-
Patent number: 10047095Abstract: The present patent application discloses at least the compounds according to Formula I? shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, ring E, ring F, JB, n, JD, J, o, RC1, RC2, W, JE, r, JF, s, Z1, Z2 and Z3 are as defined herein.Type: GrantFiled: September 16, 2015Date of Patent: August 14, 2018Assignee: Ironwood Pharmaceuticals, Inc.Inventors: Nicholas Perl, Takashi Nakai, Thomas Wai-Ho Lee, Glen Robert Rennie, Paul Allan Renhowe, Rajesh R. Iyengar
-
Publication number: 20180155345Abstract: The present patent application discloses at least the compounds according to Formula I? shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, ring E, JB, n, JD, J, X, Z, Z1, RC1, RC2, Y, R9, o and W are as defined herein.Type: ApplicationFiled: September 16, 2015Publication date: June 7, 2018Applicant: IRONWOOD PHARMACEUTICALS, INC.Inventors: Glen Robert RENNIE, Nicholas PERL, Ara MERMERIAN, Joon JUNG, James JIA, Rajesh R. IYENGAR, G-Yoon Jamie IM, Timothy Claude BARDEN, James Edward SHEPPECK, Paul Allan RENHOWE, Takashi NAKAI, Thomas Wai-Ho LEE, Karthik IYER
-
Patent number: 9969742Abstract: The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9 and pharmaceutically acceptable salt thereof. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.Type: GrantFiled: December 21, 2016Date of Patent: May 15, 2018Assignee: Ironwood Pharmaceuticals, Inc.Inventors: Matthew Gregory Bursavich, Andrew J. McRiner, Amy Ripka, Gideon Shapiro
-
Publication number: 20180015118Abstract: Disclosed herein are oral dosage forms of colesevelam, or a pharmaceutically acceptable salt thereof, adapted to treat upper gastro-intestinal disorders associated with PPI refractory GERD. Also disclosed are the methods of using these oral dosage forms to treat upper gastrointestinal disorders associated with PPI refractory, or PPI resistant, GERD in a patient in need thereof. The oral dosage forms disclosed herein are adapted for the ascribed uses by being comprised of colesevelam, or a pharmaceutically acceptable salt thereof, in a polymeric matrix comprised of one or more hydrophilic polymers such that the oral dosage form erodes upon encountering gastric fluid and has a gastric retention time of three hours or longer, allowing for an extended period of time for the colesevelam to be released in the upper GI and sequester excess bile.Type: ApplicationFiled: February 2, 2016Publication date: January 18, 2018Applicant: Ironwood Pharmaceuticals, Inc.Inventors: Bernard Joseph Lavins, Mark G Currie
-
Patent number: 9840536Abstract: Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor.Type: GrantFiled: November 9, 2015Date of Patent: December 12, 2017Assignee: Ironwood Pharmaceuticals, Inc.Inventors: Mark G. Currie, Shalina Mahajan-Miklos, Li Jing Sun
-
Publication number: 20170305878Abstract: Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.Type: ApplicationFiled: February 17, 2017Publication date: October 26, 2017Applicant: Ironwood Pharmaceuticals, Inc.Inventors: Charles KIM, Takashi NAKAI, Thomas Wai-Ho LEE, Joel MOORE, Nicholas Robert PERL, Jason ROHDE, Rajesh R. IYENGAR, Ara MERMERIAN, Angelika FRETZEN
-
Publication number: 20170298055Abstract: The present patent application discloses at least the compounds according to Formula Ia and Formula Ib shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, JB, n, J, RC1, RC2, Z1, Z2, W, X, Y1, Y2, JF and R9 are as defined herein.Type: ApplicationFiled: September 16, 2015Publication date: October 19, 2017Applicant: IRONWOOD PHARMACEUTICALS, INC.Inventors: Glen Robert RENNIE, Nicholas PERL, Thomas Wai-Ho LEE, Paul Allan RENHOWE, Takashi NAKAI, Ara MERMERIAN, G-Yoon Jamie IM
-
Publication number: 20170291902Abstract: The present patent application discloses at least the compounds according to Formula I? shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, ring E, ring F, JB, n, JD, o, RC1, RC2, W, JE, r, JF, s, Z1, Z2 and Z3 are as defined herein.Type: ApplicationFiled: September 16, 2015Publication date: October 12, 2017Applicant: IRONWOOD PHARMACEUTICALS, INC.Inventors: Nicholas PERL, Takashi NAKAI, Thomas Wai-Ho LEE, Glen Robert RENNIE, Paul Allan RENHOWE, Rajesh R. IYENGAR
-
Publication number: 20170290767Abstract: Disclosed herein are novel compositions and methods for treating or preventing upper GI tract disorders and protecting stratified squamous epithelium against injury by a noxious substance. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant, alone or in combination with at least one proton pump inhibitor, and optionally one or more agent chosen from antacids, histamine H2-receptor antagonists, ?-aminobutyricacid-b (GABA-B) agonists, prodrugs of GABA-B agonists, and protease inhibitors.Type: ApplicationFiled: December 19, 2016Publication date: October 12, 2017Applicant: Ironwood Pharmaceuticals, Inc.Inventor: Mark G. CURRIE
-
Publication number: 20170291889Abstract: Compounds are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.Type: ApplicationFiled: September 16, 2015Publication date: October 12, 2017Applicant: IRONWOOD PHARMACEUTICALS, INC.Inventors: Timothy Claude BARDEN, James Edward SHEPPECK, Glen Robert RENNIE, Paul Allan RENHOWE, Nicholas PERL, Takashi NAKAI, Ara MERMERIAN, Thomas Wai-Ho LEE, Joon JUNG, James JIA, Karthik IYER, Rajesh R. IYENGAR, G-Yoon Jamie IM
-
Publication number: 20170266116Abstract: Disclosed herein are novel compositions and methods for controlling the release of bile acid sequestrant to the stomach in order to treat or prevent upper GI tract disorders or disorders of the throat. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant dispersed in a polymeric matrix. The bile acid sequestrant composition may be administered alone or in combination with at least one proton pump inhibitor, and optionally one or more agents chosen from antacids, histamine H2-receptor antagonists, ?-aminobutyric acid-? (GABA-B) agonists, prodrugs of GABA-B agonists, acid pump antagonists, protease inhibitors and GC-C agonists.Type: ApplicationFiled: February 27, 2017Publication date: September 21, 2017Applicant: Ironwood Pharmaceuticals, Inc.Inventors: Vasu SETHURAMAN, David Bruce HEDDEN, Kristen Marie Leskow
-
Patent number: 9745296Abstract: The present invention provides amorphous arid crystalline forms of 1-ethyl-6-(indan-2-ylamino)-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one (compound 1), and salts, co-crystals, and pharmaceutical compositions thereof. The invention also provides methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using the amorphous and crystalline forms, and salts, co-crystals, and pharmaceutical compositions thereof.Type: GrantFiled: March 14, 2014Date of Patent: August 29, 2017Assignees: BIONOMICS LIMITED, IRONWOOD PHARMACEUTICALS, INC.Inventors: Bernard Luke Flynn, Dharam Paul, Andrew John Harvey, Vasu V. Sethuraman, Raymond E. Forslund, Song Xue, Rob Livingston, Ahmad Hashash